Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Among authors: dignass a. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Sands BE, et al. Among authors: dignass a. Inflamm Bowel Dis. 2024 Oct 25:izae253. doi: 10.1093/ibd/izae253. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39448057
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework.
Moreira PL, Dignass A, Estevinho MM, Portal F, Mendes J, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Jairath V, Dotan I, Magro F; International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Moreira PL, et al. Among authors: dignass a. United European Gastroenterol J. 2024 Nov;12(9):1280-1291. doi: 10.1002/ueg2.12679. Epub 2024 Oct 11. United European Gastroenterol J. 2024. PMID: 39391955 Free PMC article. Review.
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.
Parigi TL, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, Biedermann L, Colombel JF, Dignass A, Fumery M, Ghosh S, Kobayashi T, Louis E, Magro F, Panaccione R, Rausch A, Reinisch W, Selinger C, Jairath V, Danese S, Peyrin-Biroulet L. Parigi TL, et al. Among authors: dignass a. United European Gastroenterol J. 2024 Nov;12(9):1266-1279. doi: 10.1002/ueg2.12671. Epub 2024 Oct 5. United European Gastroenterol J. 2024. PMID: 39367753 Free PMC article. Review.
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.
D'Amico F, Magro F, Dignass A, Al Awadhi S, Gutierrez Casbas A, Queiroz NSF, Rydzewska G, Duk Ye B, Ran Z, Hart A, Jairath V, Fiorino G, Peyrin-Biroulet L, Danese S. D'Amico F, et al. Among authors: dignass a. Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650. Epub 2024 Sep 3. Expert Rev Gastroenterol Hepatol. 2024. PMID: 39225555 Review.
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.
Panaccione R, Ma C, Jairath V, Dignass A, Joshi N, Clark R, Griffith J, Kligys K, Semwal M, Smith Z, Mitchell D, Nunag D, Ferrante M. Panaccione R, et al. Among authors: dignass a. J Crohns Colitis. 2024 Aug 30:jjae128. doi: 10.1093/ecco-jcc/jjae128. Online ahead of print. J Crohns Colitis. 2024. PMID: 39212931
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignass A, Ehehalt R, Germer CT, Grunert PC, Helwig U, Horisberger K, Herrlinger K, Kienle P, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators. Sturm A, et al. Among authors: dignass a. Z Gastroenterol. 2024 Aug;62(8):1229-1318. doi: 10.1055/a-2309-6123. Epub 2024 Aug 7. Z Gastroenterol. 2024. PMID: 39111333 Free article. German. No abstract available.
Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease.
Sands BE, Danese S, Chapman JC, Gurjar K, Grieve S, Thakur D, Griffith J, Joshi N, Kligys K, Dignass A. Sands BE, et al. Among authors: dignass a. Inflamm Bowel Dis. 2024 Jul 31:izae159. doi: 10.1093/ibd/izae159. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39083264
324 results